^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
LBL-033
i
Other names: LBL-033
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Leads Biolabs
Drug class:
CD3 agonist, MUC16 inhibitor
Related drugs:
11ms
A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors (clinicaltrials.gov)
P1/2, N=468, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
LBL-033
1year
LBL-033, a novel bispecific antibody targeting MUC16 and CD3, for the treatment of tumors over-expressing MUC16 (AACR 2023)
LBL-033, a novel bispecific antibody targeting CD3 and MUC16 with a unique epitope, which is located at the MUC16 membrane-proximal domain, with affinity differentiation between anti-MUC16 and anti-CD3. It is shown a great anti-tumor efficacy in animal models, with a good safety profile in monkeys. These data support LBL-033 as a novel therapeutic bispecific antibody for ovarian cancer and other MUC16 positive tumors.
PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
MUC16 (Mucin 16, Cell Surface Associated)
|
MUC16 expression
|
LBL-033
Share via
